Galmed Pharmaceuticals (NASDAQ:GLMD) Now Covered by StockNews.com

StockNews.com started coverage on shares of Galmed Pharmaceuticals (NASDAQ:GLMD) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Galmed Pharmaceuticals Stock Performance

Shares of GLMD stock opened at $1.59 on Friday. The firm has a market cap of $1.02 million, a P/E ratio of -0.10 and a beta of 0.72. The firm’s 50 day moving average price is $2.37 and its 200-day moving average price is $3.37. Galmed Pharmaceuticals has a one year low of $1.38 and a one year high of $23.80.

Hedge Funds Weigh In On Galmed Pharmaceuticals

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. Schonfeld Strategic Advisors LLC bought a new stake in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 25,400 shares of the biopharmaceutical company’s stock, valued at approximately $81,000. Schonfeld Strategic Advisors LLC owned 3.97% of Galmed Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 76.14% of the company’s stock.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus.